- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: July 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in July 2027, from ClinicalTrials.gov.
Trial readouts
186 trials: 69 phase 3 (including phase 2/3) and 117 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Jul 2027 | AbbVie | Elagolix, Combined Oral ContraceptiveStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Fem… | Endometriosis | Phase 3 | Active not recruiting | NCT04333576 |
| Jul 2027 | AbbVie | Upadacitinib (ABT-494)A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | Ulcerative Colitis (UC) | Phase 3 | Active not recruiting | NCT03006068 |
| Jul 2027 | AbbVie | Venetoclax, AzacitidineStudy Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newl… | Myelodysplastic Syndrome (MDS) | Phase 3 | Active not recruiting | NCT04401748 |
| Jul 2027 | Alvotech Swiss AG | AVT29 (proposed aflibercept HD biosimilar), Eylea HD (aflibercept HD)Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema | Diabetic Macular Edema | Phase 3 | Recruiting | NCT07489131 |
| Jul 2027 | Amicus Therapeutics | Cipaglucosidase alfa, MiglustatA Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 | Glycogen Storage Disease Type II Infantile Onset | Phase 3 | Recruiting | NCT04808505 |
| Jul 2027 | Apellis Pharmaceuticals, Inc. | PegcetacoplanAn Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants Wit… | C3G, IC-MPGN and 10 more | Phase 3 | Active not recruiting | NCT05809531 |
| Jul 2027 | Biocells (Beijing) Biotech Co.,Ltd | BXOS110A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 In… | AIS | Phase 3 | Recruiting | NCT07520565 |
| Jul 2027 | Biotheus Inc. | PM8002, Nab-PaclitaxelPM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | Triple Negative Breast Cancer(TNBC) | Phase 3 | Active not recruiting | NCT06419621 |
| Jul 2027 | Caliway Biopharmaceuticals Co., Ltd. | CBL-514 Injection, 0.9% Sodium ChlorideA Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat | Subcutaneous Fat | Phase 3 | Recruiting | NCT07140939 |
| Jul 2027 | Eli Lilly and Company | RetatrutideA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Obesity, Overweight | Phase 3 | Active not recruiting | NCT07232719 |
| Jul 2027 | GL Pharm Tech Corporation | W2505, W2505-P1, W2505-R and 1 moreThe Purpose of This Study is to Evaluate the Efficacy and Safety of W2505. | Erectile Dysfunctions | Phase 3 | Not yet recruiting | NCT07859202 |
| Jul 2027 | Infectopharm Arzneimittel GmbH | 5% Permethrin Creme, 10% Permethrin CremeTherapy for Scabies With Two Differently Concentrated Permethrin Creams | Scabies | Phase 3 | Not yet recruiting | NCT06380452 |
| Jul 2027 | Intellia Therapeutics | nexiguran ziclumeranA Phase 3 Study of NTLA-2001 in ATTRv-PN | Neuromuscular Disease, Neuromuscular Diseases (NMD) and 18 more | Phase 3 | Recruiting | NCT06672237 |
| Jul 2027 | Mesoblast | Rexlemestrocel-L + HA mixtureEfficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain | Degenerative Disc Disease | Phase 3 | Active not recruiting | NCT06325566 |
| Jul 2027 | Nervgen Pharma Corp. | NVG-291A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury | Chronic Spinal Cord Injury | Phase 3 | Recruiting | NCT07799532 |
| Jul 2027 | Neurocrine Biosciences | NBI-1065845NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive… | Major Depressive Disorder | Phase 3 | Recruiting | NCT06963021 |
| Jul 2027 | Neurocrine Biosciences | NBI-1065845NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive… | Major Depressive Disorder | Phase 3 | Recruiting | NCT06911112 |
| Jul 2027 | Neurocrine Biosciences | NBI-1065845Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Major Depressive Disorder | Phase 3 | Recruiting | NCT06786624 |
| Jul 2027 | PT. Prodia Stem Cell Indonesia | 1.5 x 10^6 UC-MSC + CM, 5 x 10^6 UC-MSC + CMRole of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II | Retinitis Pigmentosa | Phase 2/3 | Not yet recruiting | NCT05909488 |
| Jul 2027 | Paradigm Biopharmaceuticals Limited.. | Pentosan Polysulfate Sodium twice weeklyA Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Partici… | Osteoarthritis, Knee | Phase 3 | Active not recruiting | NCT06917404 |
| Jul 2027 | SANGMYUNG innovation | Reference Drug, SMO1Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema | Retinal Vein Occlusion With Macular Edema | Phase 3 | Recruiting | NCT07708142 |
| Jul 2027 | Shanghai Henlius Biotech | HLX15-IV, DarzalexA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-i… | Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | NCT06895512 |
| Jul 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB264, Nab-paclitaxel, Paclitaxel and 1 moreA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/H… | Metastatic Breast Cancer | Phase 3 | Recruiting | NCT07071337 |
| Jul 2027 | Sinocelltech Ltd. | SCTB14, PembrolizumabA Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | Non-Small Cell Lung Carcinoma (NSCLC) | Phase 3 | Recruiting | NCT07362459 |
| Jul 2027 | Sinovac Biotech | Sinovac PCV13, Prevenar 13™Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days) | Pneumococcal Infectious Diseases | Phase 3 | Not yet recruiting | NCT07593924 |
| Jul 2027 | Sunshine Lake Pharma Co., Ltd. | Mitizodone Phosphate tabletsThe Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | Depressive Disorder, Major | Phase 2/3 | Recruiting | NCT04984512 |
| Jul 2027 | Telix Pharmaceuticals Limited | TLX-101-Tx + Lomustine, TLX101-TxStudy of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma | Neoplastic Disease, Glioblastoma and 4 more | Phase 3 | Recruiting | NCT07100730 |
| Jul 2027 | Trust Bio-sonics, Inc. | NH002 (Perflutren Lipid Microspheres) Injectable SuspensionA Prospective, Multicenter, Phase III Clinical Evaluation of the Safety and Efficacy of NH002 as a Contrast Agent Administrated Via Intraven… | Cardiac Diseases | Phase 3 | Not yet recruiting | NCT07740421 |
| Jul 2027 | Viatris | SelatogrelSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | Acute Myocardial Infarction | Phase 3 | Enrolling by invitation | NCT04957719 |
| Jul 2027 | Argenx SE | Efgartigimod PH20 SCA Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome | Primary Sjogrens Disease | Phase 3 | Active not recruiting | NCT06684847 |
| Jul 1, 2027 | Rapa Therapeutics LLC | RAPA-501 Autologous T stem cellsRAPA-501 Therapy for ALS | Amyotrophic Lateral Sclerosis | Phase 2/3 | Recruiting | NCT04220190 |
| Jul 1, 2027 | Shanghai Yizhong Pharmaceutical Co., Ltd. | paclitaxel polymeric micelles for injection, Gemcitabine Hydrochloride for Injection, Paclitaxel for Injection (albumin bound )Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer | Pancreatic Cancer Metastatic | Phase 3 | Recruiting | NCT06752811 |
| Jul 1, 2027 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | XY0206, Salvage ChemotherapyA Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) | Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 3 | Not yet recruiting | NCT05876832 |
| Jul 1, 2027 | Viking Therapeutics | VK2735VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Weight Loss | Phase 3 | Active not recruiting | NCT07104383 |
| Jul 1, 2027 | Viking Therapeutics | VK2735VK2735 for Weight Management Phase 3 | Weight Loss | Phase 3 | Active not recruiting | NCT07104500 |
| Jul 5, 2027 | Amgen | Tarlatamab, DurvalumabStudy Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following P… | Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Phase 3 | Active not recruiting | NCT06211036 |
| Jul 6, 2027 | Lundbeck | EptinezumabA Study of Eptinezumab in Pediatric Participants With Episodic Migraine | Episodic Migraine | Phase 3 | Recruiting | NCT05897320 |
| Jul 9, 2027 | Chendu DIAO Pharmaceutical Group CO., LTD. | DA-302168SA Study of DA-302168S in Participants With Overweight/Obesity | Overweight and Obesity | Phase 3 | Recruiting | NCT07629544 |
| Jul 9, 2027 | GSK | mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age | Influenza, Human | Phase 3 | Recruiting | NCT07851246 |
| Jul 9, 2027 | Sanofi | riliprubart, IVIgA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chron… | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Recruiting | NCT06290141 |
| Jul 10, 2027 | Akeso | –A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis | Atopic Dermatitis | Phase 3 | Not yet recruiting | NCT06767540 |
| Jul 11, 2027 | Merck & Co. | Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel and 3 moreA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician… | Breast Neoplasms | Phase 3 | Recruiting | NCT06312176 |
| Jul 12, 2027 | InventisBio Co., Ltd | D-2570 Tablet, BMS-986165 TabletA Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Phase 3 | Recruiting | NCT07326813 |
| Jul 14, 2027 | Merck & Co. | Bomedemstat, Anagrelide, Busulfan and 2 moreA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Ina… | Essential Thrombocythemia | Phase 3 | Active not recruiting | NCT06079879 |
| Jul 15, 2027 | AstraZeneca | Acalabrutinib, Venetoclax, ObinutuzumabA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small L… | Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | Active not recruiting | NCT05057494 |
| Jul 15, 2027 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Trilaciclib, Etoposide Injection, Carboplatin or Cisplatin Injection and 1 moreA Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With L… | Myelosuppression | Phase 3 | Active not recruiting | NCT07881705 |
| Jul 15, 2027 | Sanofi | Frexalimab, MRI contrast-enhancing preparationsNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple S… | Multiple Sclerosis | Phase 3 | Recruiting | NCT07325292 |
| Jul 18, 2027 | Amgen | AvacopanStudy to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of… | Vasculitis | Phase 3 | Active not recruiting | NCT06321601 |
| Jul 20, 2027 | Roche Holding | PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchangeA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Mac… | Diabetic Macular Edema | Phase 3 | Active not recruiting | NCT04108156 |
| Jul 22, 2027 | Danyang Huichuang Medical Equipment Co., Ltd. | NirsCure 6000, Sham DeviceNear-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A) | Alzheimer s Disease | Phase 3 | Recruiting | NCT07262645 |
| Jul 22, 2027 | Merck & Co. | MK-8527, FTC/TDFA Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) | Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 3 | Active not recruiting | NCT07044297 |
| Jul 22, 2027 | Pfizer | PF-07248144, Fulvestrant, Everolimus and 1 moreA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advan… | Breast Cancer | Phase 3 | Recruiting | NCT07062965 |
| Jul 23, 2027 | Sanofi | RilzabrutinibThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | Sickle Cell Disease | Phase 3 | Recruiting | NCT06975865 |
| Jul 27, 2027 | AstraZeneca | BaxdrostatParent Study: A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism Sub-study: A Follow-up Substudy… | Primary Hyperaldosteronism | Phase 3 | Active not recruiting | NCT07007793 |
| Jul 28, 2027 | AstraZeneca | Dato-DXd, Durvalumab, Paclitaxel and 4 moreA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizum… | Breast Cancer | Phase 3 | Recruiting | NCT06103864 |
| Jul 28, 2027 | InventisBio Co., Ltd | D-2570Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis | Plaque Psoriasis | Phase 3 | Recruiting | NCT07130604 |
| Jul 30, 2027 | AstraZeneca | Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 and 2 moreA Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT… | Hypercholesterolaemia | Phase 3 | Recruiting | NCT07619131 |
| Jul 30, 2027 | Bayer | Darolutamide (BAY1841788, Nubeqa), ADTA Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prost… | Biochemically Recurrent Prostate Cancer | Phase 3 | Active not recruiting | NCT05794906 |
| Jul 30, 2027 | Genmab A/s | Acasunlimab, Pembrolizumab, DocetaxelTrial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL… | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Phase 3 | Active not recruiting | NCT06635824 |
| Jul 30, 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK16149 20mg-40mg BIDEfficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China | Central Neuropathic Pain | Phase 3 | Not yet recruiting | NCT06422117 |
| Jul 30, 2027 | Johnson & Johnson | Talquetamab, Daratumumab, Pomalidomide and 1 moreA Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Comb… | Multiple Myeloma | Phase 3 | Active not recruiting | NCT05455320 |
| Jul 30, 2027 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | GP681 40mg, GP681 SimulantStudy to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | Influenza | Phase 3 | Recruiting | NCT06574503 |
| Jul 30, 2027 | Pfizer | RitlecitinibA 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2 | Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo | Phase 3 | Active not recruiting | NCT06072183 |
| Jul 30, 2027 | Shanghai Bovax Biotechnology Co., Ltd. | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33…A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | Genital Wart, Penile Cancer and 8 more | Phase 3 | Active not recruiting | NCT06465914 |
| Jul 31, 2027 | Amgen | ABP 938 8 mg, Aflibercept (US) 8 mgA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular A… | Neovascular Age-related Macular Degeneration, nAMD | Phase 3 | Recruiting | NCT07614776 |
| Jul 31, 2027 | Annexon, Inc. | Vonaprument, Sham AdministrationA Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age… | Geographic Atrophy | Phase 3 | Active not recruiting | NCT06510816 |
| Jul 31, 2027 | MAIA Biotechnology, Inc. | 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel and 2 moreA Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | Carcinoma, Non-Small -Cell Lung | Phase 3 | Recruiting | NCT06908304 |
| Jul 31, 2027 | Shionogi | SecutrelvirStudy of Secutrelvir in Participants With COVID-19 | COVID-19 | Phase 3 | Recruiting | NCT07746544 |
| Jul 31, 2027 | Taisho Pharmaceutical Co., Ltd. | TS-172A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis | Hyperphosphatemia Patients on Hemodialysis | Phase 3 | Recruiting | NCT07285304 |
| Jul 2027 | ARTHEx Biotech S.L. | ATX-01Study of ATX-01 in Participants With DM1 | Myotonic Dystrophy 1 | Phase 1/2 | Recruiting | NCT06300307 |
| Jul 2027 | Advesya SAS | CCTx-001An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerabilit… | Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 1/2 | Not yet recruiting | NCT06281847 |
| Jul 2027 | Alkermes | ALKS 7290A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disord… | Attention Deficit Disorder With Hyperactivity (ADHD) | Phase 2 | Recruiting | NCT07755410 |
| Jul 2027 | Amydis Inc. | AMDX-2011PA Study of AMDX-2011P in Participants With Alzheimer's Disease | Alzheimer Disease | Phase 2 | Recruiting | NCT06514001 |
| Jul 2027 | Anagram Therapeutics, Inc. | ANG003 Dose A, ANG003 Dose B, CreonPhase 2 Study to Assess the Safety and Efficacy of ANG003 | Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Recruiting | NCT07450547 |
| Jul 2027 | Arrowhead Pharmaceuticals | ARO-DIMERPAStudy of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | Hyperlipidemia; Mixed | Phase 1/2 | Recruiting | NCT07223658 |
| Jul 2027 | Sino Biopharmaceutical Limited | TQD3524, Meropenem for injection, Colistimethate Sodium for InjectionStudy on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ve… | Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia | Phase 2 | Recruiting | NCT07512596 |
| Jul 2027 | Cilcare SAS | CIL001 (Paliroden)A Study Testing the Safety and Possible Benefits of an Ear Injection of a New Compound, Paliroden, in People With Type 2 Diabetes Who Have D… | Cochlear Synaptopathy | Phase 1/2 | Not yet recruiting | NCT07472907 |
| Jul 2027 | Crystalys Therapeutics | DotinuradA Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants | Gout | Phase 2 | Recruiting | NCT07535034 |
| Jul 2027 | Curis Inc | Emavusertib, IbrutinibCA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous Syst… | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy and 2 more | Phase 1/2 | Recruiting | NCT03328078 |
| Jul 2027 | Defibrio, LLC | treatment with Defibrio AEDDefibrio AED Study | VF, VT | Phase 1/2 | Not yet recruiting | NCT07880873 |
| Jul 2027 | Dizal Pharmaceuticals | DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) | Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | NCT07294365 |
| Jul 2027 | Eli Lilly and Company | LY4065967A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain | Diabetic Peripheral Neuropathic Pain | Phase 2 | Recruiting | NCT07285018 |
| Jul 2027 | Eli Lilly and Company | LY3537031A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C) | Irritable Bowel Syndrome, Constipation | Phase 2 | Recruiting | NCT07545772 |
| Jul 2027 | Genfleet Therapeutics (Shanghai) Inc. | GFH375A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | Advanced Solid Tumors Cancer, PDAC and 1 more | Phase 1/2 | Recruiting | NCT07259590 |
| Jul 2027 | Genmab A/s | Rina-S, Carboplatin, Bevacizumab and 3 moreRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer and 14 more | Phase 1/2 | Recruiting | NCT05579366 |
| Jul 2027 | Graviton Bioscience Corporation | GV101GV101 for Friedreich's Ataxia (FA) Treatment | Friedreich's Ataxia | Phase 2 | Not yet recruiting | NCT07870590 |
| Jul 2027 | Jiangsu Hengrui Medicine | SHR-1139, SHR-1139 and SHR-1139 pleaceboA Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis | Plaque Psoriasis | Phase 2 | Not yet recruiting | NCT07758075 |
| Jul 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK44459 tabletsA Long-term Study of HSK44459 Tablets in Participants With Bechet's Disease | Bechet's Disease | Phase 2 | Not yet recruiting | NCT07070739 |
| Jul 2027 | Haisco Pharmaceutical Group Co., Ltd. | HSK39004 Dry Powder Inhaler -0.75mg BIDLong-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD | Chronic Obstructive Lung Disease (COLD) | Phase 2 | Not yet recruiting | NCT07425210 |
| Jul 2027 | Hemab ApS | HMB-002 (Part A), HMB-002 (Part B), HMB-002 with Concomitant Factor Concentrate (Part C) (Not …A Study Assessing HMB-002 in Participants With Von Willebrand Disease | Von Willebrand Disease (VWD), Von Willebrand Disease (VWD), Type 1 and 2 more | Phase 1/2 | Recruiting | NCT06754852 |
| Jul 2027 | Hummingbird Bioscience | ENV-501A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-E… | Melanoma (Skin), Non Small Cell Lung Cancer and 1 more | Phase 1/2 | Recruiting | NCT06956690 |
| Jul 2027 | Incyclix Bio | INX-315, Fulvestrant, AbemaciclibOpen-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Breast Cancer, Breast Cancer Metastatic and 7 more | Phase 1/2 | Recruiting | NCT05735080 |
| Jul 2027 | Jiangsu Hengrui Medicine | SHR4640 ；Febuxostat, SHR4640 ; Febuxostat, SHR4640 and 1 moreThe Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia | Primary Gout and Hyperuricemia | Phase 2 | Recruiting | NCT07362355 |
| Jul 2027 | Gilead Sciences | KTE-X19, Cyclophosphamide, FludarabineStudy of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymph… | Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | NCT06253663 |
| Jul 2027 | Krystal Biotech, Inc. | KB707, Opdualag, KEYTRUDA ®( Pembrolizumab)A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Cancer, Melanoma Stage III and 2 more | Phase 1/2 | Recruiting | NCT05970497 |
| Jul 2027 | Mabwell (Shanghai) Bioscience Co., Ltd. | 7MW4911First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors | Solid Tumors | Phase 1/2 | Recruiting | NCT07265622 |
| Jul 2027 | Mabwell (Shanghai) Bioscience Co., Ltd. | 7MW4911First-in-human Study of 7MW4911 in GI Cancer | GI Cancers | Phase 1/2 | Recruiting | NCT07216560 |
| Jul 2027 | Macrogenics Inc | LorigerlimabA Study of Lorigerlimab in Participants With Advanced Solid Tumors | Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma and 9 more | Phase 2 | Recruiting | NCT06730347 |
| Jul 2027 | PT. Prodia Stem Cell Indonesia | Umbilical Cord Mesenchymal Stem CellsSafety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy in Diabetic Nephropathy Patients: A Clinical Trial | Diabetic Nephropathy Type 2 | Phase 1/2 | Recruiting | NCT07396155 |
| Jul 2027 | Q Therapeutics, Inc. | Q-CellsStudy to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis | Transverse Myelitis | Phase 1/2 | Recruiting | NCT03887273 |
| Jul 2027 | Qilu Pharmaceutical Co., Ltd. | QLS5133A Study of QLS5133 Monotherapy in Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Not yet recruiting | NCT07061639 |
| Jul 2027 | Reunion Neuroscience | RE104 for InjectionRE104 Safety and Efficacy Study in Generalized Anxiety Disorder | Generalized Anxiety Disorder | Phase 2 | Recruiting | NCT07489651 |
| Jul 2027 | Ribocure Pharmaceuticals AB | VortosiranVortosiran for VTE Prevention | Venous Thromboembolism (VTE), Cancer and 1 more | Phase 2 | Not yet recruiting | NCT07850453 |
| Jul 2027 | Sangamo Therapeutics, Inc | ST-503, Sham (No Treatment)Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN) | Chronic Neuropathic Pain | Phase 1/2 | Recruiting | NCT06980948 |
| Jul 2027 | Sensorion | SENS-501 administrationA Phase I/II Clinical Trial With SENS-501 in Children Suffering From Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations | OTOF Gene Mutation, DFNB9 and 6 more | Phase 1/2 | Active not recruiting | NCT06370351 |
| Jul 2027 | Sichuan Baili Pharmaceutical Co., Ltd. | BL-B01D1, Osimertinib Mesylate TabletsA Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small … | Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT05880706 |
| Jul 2027 | Sitala Bio LTD | STL303Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy | IgAN | Phase 2 | Recruiting | NCT07606352 |
| Jul 2027 | Jiangsu Hengrui Medicine | SHR-8068 Injection, Adebrelimab Injection, Apatinib Mesylate TabletsA Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma | Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk | Phase 2 | Not yet recruiting | NCT07682272 |
| Jul 2027 | Tiziana Life Sciences Ltd | Foralumab NasalThe BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab | ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis and 1 more | Phase 2 | Not yet recruiting | NCT07688239 |
| Jul 2027 | Travere Therapeutics, Inc. | PegtibatinasePegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study) | Homocystinuria | Phase 1/2 | Recruiting | NCT03406611 |
| Jul 2027 | Vantage Biosciences Ltd | VX-01A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy | Phase 2 | Active not recruiting | NCT06770933 |
| Jul 2027 | Wuhan Createrna Science and Technology Co., Ltd | MY008211A tabletsStudy of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Not yet recruiting | NCT06134414 |
| Jul 2027 | XellSmart Therapeutics (Shanghai) Co., Ltd. | human allogeneic induced pluripotent stem cell (iPSC)-deri…The Safety,Tolerability, Efficacy of XS411 Cell Injection for the Treatment of Primary Parkinson's Disease | Parkinson's Disease | Phase 1/2 | Active not recruiting | NCT07080775 |
| Jul 1, 2027 | Connext | [Step1] CNT201 First-dose, [Step1] CNT201 Low-dose, [Step1] CNT201 Intermediate-dose and 2 moreSafety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture | Dupuytren Contracture, Dupuytren Disease of Finger | Phase 1/2 | Recruiting | NCT07640425 |
| Jul 1, 2027 | CSPC Pharmaceutical Group | CM326 dose 1, CM326 dose 2A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | Phase 2 | Recruiting | NCT07418736 |
| Jul 1, 2027 | E-Star BioTech, LLC | MANPTo Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension | Difficult to Control Hypertension | Phase 2 | Recruiting | NCT06343298 |
| Jul 1, 2027 | EpicentRx, Inc. | RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | Oral Mucositis | Phase 2 | Active not recruiting | NCT05966194 |
| Jul 1, 2027 | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | GR1803GR1803 Injection in Patients With RRMM | Multiple Myleoma | Phase 2 | Recruiting | NCT06952075 |
| Jul 1, 2027 | ProDa BioTech, LLC | ProAgio Dose Levels (DL) 1,2,3,4, ProAgio Dose ExpansionProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer | Triple Negative Breast Cancer | Phase 1/2 | Recruiting | NCT06460298 |
| Jul 1, 2027 | VelaVigo Bio Inc | VBC101First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies | Participants With Advanced Solid Tumor Malignancies | Phase 1/2 | Recruiting | NCT07136779 |
| Jul 1, 2027 | Vincentage Pharma Co., Ltd | VCT220 tabletsA Study of VCT220 Tablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control | Type 2 Diabetes Mellitus (DM) | Phase 2 | Not yet recruiting | NCT07872436 |
| Jul 2, 2027 | AstraZeneca | ALXN1920Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Phase 2 | Recruiting | NCT07157787 |
| Jul 6, 2027 | Regeneron Pharmaceuticals | REGN5093A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | NSCLC | Phase 1/2 | Active not recruiting | NCT04077099 |
| Jul 7, 2027 | AstraZeneca | AZD2389Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis | Liver Fibrosis, Hepatic Cirrhosis | Phase 2 | Recruiting | NCT07610837 |
| Jul 7, 2027 | Chengdu SciMount Pharmatech Co., Ltd. | SMP-656 InjectionSMP-656 for HER2-Positive Advanced Breast Cancer | HER2-positive Breast Cancer, Metastatic Breast Cancer and 1 more | Phase 2 | Recruiting | NCT07726342 |
| Jul 7, 2027 | Epicrispr Biotechnologies, Inc. | EPI-321A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy | Facioscapulohumeral Muscular Dystrophy | Phase 1/2 | Active not recruiting | NCT06907875 |
| Jul 7, 2027 | Kailera Therapeutics, Inc. | KAI-7535Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity | Obesity, Overweight | Phase 2 | Active not recruiting | NCT07497880 |
| Jul 9, 2027 | Nanjing Immunophage Biotech Co., Ltd | IPG1094Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients | Solid Tumor | Phase 1/2 | Recruiting | NCT06212076 |
| Jul 10, 2027 | Cell Energy Life Sciences Group Co. LTD | mesenchymal stem cellMesenchymal Stem Cells Treatment for AIDS Patients at Late Stage | AIDS | Phase 1/2 | Recruiting | NCT05939167 |
| Jul 10, 2027 | Hansoh Pharmaceutical Group | HS-10516 + LenvatinibStudy of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Phase 1/2 | Recruiting | NCT07097935 |
| Jul 13, 2027 | Evopoint Biosciences Inc. | XNW5004, enzalutamideStudy of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | Metastatic Castrate-Resistant Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 1/2 | Recruiting | NCT06702995 |
| Jul 14, 2027 | BioInvent International AB | BI-1910, PembrolizumabBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | Solid Tumors, Non Small Cell Lung Cancer and 1 more | Phase 1/2 | Active not recruiting | NCT06205706 |
| Jul 14, 2027 | GSK | MomelotinibA Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome | Myelodysplastic Syndromes | Phase 2 | Recruiting | NCT06847867 |
| Jul 15, 2027 | Ausper Biopharma Co., Ltd. | AHB-137, Peg-IFN, Hepatitis B VaccineA Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs | Chronic Hepatitis B | Phase 2 | Recruiting | NCT07069569 |
| Jul 15, 2027 | Azitra, Inc. | ATR04-484A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity | EGFR Inhibitor-associated Rash | Phase 1/2 | Recruiting | NCT06830863 |
| Jul 16, 2027 | Bristol-Myers Squibb | LuspaterceptA Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Ad… | Anemia | Phase 2 | Active not recruiting | NCT05664737 |
| Jul 16, 2027 | GV20 Therapeutics | GV20-0251Study of GV20-0251 in Participants With Solid Tumor Malignancies | Solid Tumor Cancer, Adult Refractory Cancer and 7 more | Phase 1/2 | Recruiting | NCT07070518 |
| Jul 16, 2027 | Longbio Pharma (Suzhou) Co., Ltd. | LP-003 InjectionA Study to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Characteristics of LP-003 Injection in Participants With Wheat… | Food Allergy, Wheat Hypersensitivity | Phase 2 | Not yet recruiting | NCT07816432 |
| Jul 16, 2027 | Novartis | JSB462, AAA617A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Ca… | Prostatic Cancer, Castration-Resistant | Phase 2 | Active not recruiting | NCT07047118 |
| Jul 18, 2027 | Rare Thyroid Therapeutics International AB | TiratricolTriac Trial II in MCT8 Deficiency Patients | Allan-Herndon-Dudley Syndrome | Phase 2 | Active not recruiting | NCT02396459 |
| Jul 20, 2027 | Daiichi Sankyo | Ifinatamab deruxtecan, Atezolizumab, CarboplatinA Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extens… | Extensive Stage-small Cell Lung Cancer | Phase 1/2 | Recruiting | NCT06362252 |
| Jul 21, 2027 | Keymed Biosciences Co.Ltd | CM512 injectionStudy of CM512 Injection in Subjects With Moderate-to-severe Asthma | Asthma | Phase 2 | Recruiting | NCT07011524 |
| Jul 21, 2027 | Recordati Group | LCI699Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | Cushing Syndrome | Phase 2 | Recruiting | NCT03708900 |
| Jul 22, 2027 | Novartis | EYU688A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever | Dengue | Phase 2 | Recruiting | NCT06006559 |
| Jul 22, 2027 | Novartis | LXE408, BenznidazoleA Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. | Chagas Disease | Phase 2 | Recruiting | NCT06632600 |
| Jul 22, 2027 | Vertex Pharmaceuticals | VX-407Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Active not recruiting | NCT07161037 |
| Jul 25, 2027 | Sirnaomics | STP705STP705 Injection for Submental Fat Reduction | Submental Fullness | Phase 2 | Recruiting | NCT07677683 |
| Jul 27, 2027 | Ausper Biopharma Co., Ltd. | AHB-137A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | Phase 2 | Active not recruiting | NCT06993480 |
| Jul 28, 2027 | Shanghai Henlius Biotech | HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab and 1 moreA Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer | Colon Cancer Adenocarcinoma | Phase 1/2 | Not yet recruiting | NCT07358585 |
| Jul 29, 2027 | EIR Biotherapies s.r.l. | RR001Phase I/IIa Study: RR001 Administered Following Chemotherapy Cycles for Patients With Locally Advanced Pancreatic Carcinoma | Locally Advanced Pancreatic Adenocarcinoma | Phase 1/2 | Recruiting | NCT06861452 |
| Jul 29, 2027 | GSK | GSK3772701 600 mg, GSK3772701 900 mg, GSK3772701 150 mg and 2 moreA Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria | Malaria, Falciparum | Phase 2 | Not yet recruiting | NCT07545681 |
| Jul 29, 2027 | Novartis | GXV813Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia | Schizophrenia | Phase 2 | Recruiting | NCT07467993 |
| Jul 30, 2027 | AstraZeneca | Volrustomig, Carboplatin, Pemetrexed and 2 moreVolrustomig Priming Regimens Exploratory Phase II Platform Study | Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT06448754 |
| Jul 30, 2027 | Boehringer Ingelheim | BI 3032950 intravenous (Part A), BI 3032950 subcutaneous (Part B)A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis | Ulcerative Colitis | Phase 2 | Recruiting | NCT06636656 |
| Jul 30, 2027 | CSPC Pharmaceutical Group | SYS6045Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expre… | Advanced Solid Tumors | Phase 1/2 | Active not recruiting | NCT07122063 |
| Jul 30, 2027 | Chengdu Syncor Pharmaceutical Co., Ltd. | BPR-6023021 for injectionA Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases | Metastatic Solid Tumors | Phase 1/2 | Not yet recruiting | NCT07249892 |
| Jul 30, 2027 | Chengdu Zenitar Biomedical Technology Co., Ltd | Flonoltinib 75mg, Flonoltinib 100mg, Flonoltinib 125mg and 1 morePhase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera | Polycythemia Vera (PV) | Phase 2 | Recruiting | NCT07232290 |
| Jul 30, 2027 | Direct Biologics, LLC | DB-3QDB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease | Perianal Fistula Due to Crohn's Disease | Phase 2 | Recruiting | NCT06918808 |
| Jul 30, 2027 | Roche Holding | Atezolizumab, BevacizumabA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 a… | Hepatocellular Carcinoma | Phase 2 | Active not recruiting | NCT06096779 |
| Jul 30, 2027 | Roche Holding | Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab and 10 moreA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (M… | Advanced Liver Cancers | Phase 1/2 | Active not recruiting | NCT04524871 |
| Jul 30, 2027 | Incyte | INCB000928To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva | Fibrodysplasia Ossificans Progressiva (FOP) | Phase 2 | Recruiting | NCT05090891 |
| Jul 30, 2027 | Lingyi Biotech Co., Ltd. | LY-M001A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease | Gaucher Disease Type 1 | Phase 1/2 | Recruiting | NCT06818838 |
| Jul 30, 2027 | MediLink Therapeutics (Suzhou) Co., Ltd. | YL202 should be intravenously infusedA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC | Locally Advanced or Metastatic Breast Cancer | Phase 2 | Recruiting | NCT06439771 |
| Jul 30, 2027 | Novartis | Glycopyrronium bromide 25ug, Glycopyrronium bromide 12.5ugPharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma | Asthma | Phase 2 | Recruiting | NCT05222529 |
| Jul 30, 2027 | Novartis | Capmatinib, Nazartinib, Gefitinib and 1 moreStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or… | Advanced Solid Tumors Which Are cMET-dependent | Phase 2 | Active not recruiting | NCT03040973 |
| Jul 30, 2027 | Novartis | IanalumabA Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis | Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Active not recruiting | NCT06470048 |
| Jul 30, 2027 | Oncolytics Biotech | Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel and 2 moreA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified and 2 more | Phase 1/2 | Active not recruiting | NCT07280377 |
| Jul 30, 2027 | Sinocelltech Ltd. | SCTV02A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine | Respiratory Syncytial Virus | Phase 1/2 | Recruiting | NCT06754605 |
| Jul 30, 2027 | Jiangsu Hengrui Medicine | Almonertinib combined with SHR-1701, AlmonertinibPhase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer | Relapsed or Advanced Non-small Cell Lung Cancer | Phase 1/2 | Not yet recruiting | NCT05503888 |
| Jul 30, 2027 | Throne Biotechnologies Inc. | Stem Cell Educator therapyClinical Application of Stem Cell Educator Therapy in Alopecia Areata | Alopecia Areata, Alopecia Totalis and 1 more | Phase 2 | Active not recruiting | NCT04011748 |
| Jul 30, 2027 | Tianjin ConjuStar Biologics Co., Ltd. | SC-101SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers | TNBC - Triple-Negative Breast Cancer, HR+ Breast Cancer | Phase 2 | Not yet recruiting | NCT07080619 |
| Jul 31, 2027 | Beijing Bio-Targeting Therapeutics Technology Co., Ltd | BioTTT001 injectionEvaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma. | Recurrent High-grade Glioma | Phase 1/2 | Enrolling by invitation | NCT06763965 |
| Jul 31, 2027 | Beijing Inno Medicine Co., Ltd. | –A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis | Atherosclerosis, Coronary Artery Disease | Phase 2 | Recruiting | NCT07521007 |
| Jul 31, 2027 | Cidara Therapeutics | MK-1406 InjectionA Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) | Healthy Participants | Phase 2 | Active not recruiting | NCT07225959 |
| Jul 31, 2027 | Estrella Immunopharma, Inc. | EB103T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) | B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins and 13 more | Phase 1/2 | Recruiting | NCT06343311 |
| Jul 31, 2027 | Roche Holding | Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), TocilizumabA Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies | Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | NCT05207670 |
| Jul 31, 2027 | Hangzhou Highlightll Pharmaceutical Co., Ltd | TLL-018TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs | Rheumatoid Arthritis (RA) | Phase 2 | Enrolling by invitation | NCT07748728 |
| Jul 31, 2027 | Henan Genuine Biotech Co., Ltd. | GEN-725 tablets + Dositinib mesylate tabletsA Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib | Non-Small Cell Lung Cancer | Phase 1/2 | Recruiting | NCT07362940 |
| Jul 31, 2027 | HepaRegeniX GmbH | HRX215 capsulesSafety of HRX215 in Patients After Minor and Major Liver Resection | Liver Resection, Colorectal Carcinoma Liver Metastases | Phase 1/2 | Recruiting | NCT06638502 |
| Jul 31, 2027 | Roche Holding | Inavolisib, Ribociclib, Letrozole and 1 moreA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | Breast Cancer | Phase 2 | Recruiting | NCT07054190 |
| Jul 31, 2027 | Roche Holding | RO7126209Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO712620… | Alzheimers Disease | Phase 1/2 | Active not recruiting | NCT04639050 |
| Jul 31, 2027 | MediLink Therapeutics (Suzhou) Co., Ltd. | intravenous (IV) infusionA Clinical Study of YL205 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06459973 |
| Jul 31, 2027 | Shanghai Vitalgen BioPharma Co., Ltd. | VGR-R01A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD) | Bietti Crystalline Dystrophy | Phase 1/2 | Not yet recruiting | NCT07586306 |
| Jul 31, 2027 | SpectraCure AB | Verteporfin, SpectraCure P18 SystemClinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | Recurrent Prostate Cancer | Phase 1/2 | Recruiting | NCT03067051 |
| Jul 31, 2027 | Stingray Therapeutics | SR-8541APhase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colo… | Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) | Phase 2 | Recruiting | NCT06589440 |
| Jul 31, 2027 | TG Therapeutics | Ublituximab, Prefilled penA Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative B… | Multiple Sclerosis | Phase 2 | Recruiting | NCT07503873 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.